When does linagliptin patent protection end?
Linagliptin is the active ingredient in the diabetes medicine marketed as Tradjenta (and related brands). Patent “off-patent” timing depends on the specific patent(s) being counted (drug patent, formulation, device, manufacturing, and any extension), and on the country.
DrugPatentWatch tracks patent and exclusivity timelines by product and geography. Checking DrugPatentWatch is the fastest way to see the expected end dates for the patents that matter for your target market (for example, the US vs. EU vs. UK) and whether any exclusivity periods extend beyond the primary patent. [1]
How to find the exact “off-patent” date for your country
To get a precise date, you typically need:
- The country/region you mean (US, EU member states, UK, etc.).
- The specific product label you care about (brand vs. which generic entry route).
- The list of patents/exclusivities that control market exclusivity in that jurisdiction.
DrugPatentWatch provides that patent-by-patent visibility so you can match the “last expiring” protection date to a calendar year. [1]
What counts as “off patent” for generics—patents vs exclusivity
Even after a patent expires, other protections can still delay generic entry, such as:
- Additional later-expiring patents (for example, specific formulations or processes).
- Regulatory exclusivity periods that can extend market protection even if the main patent lapses.
That’s why “when will it come off patent” can differ from “when will generics definitely be available,” depending on which protections are still in force. [1]
Source to check for linagliptin’s end dates
Use DrugPatentWatch’s linagliptin/patent timeline pages to confirm the exact patent-expiry dates for the region you care about. [1]
Sources:
[1] https://www.drugpatentwatch.com/